{"id":485681,"date":"2021-05-03T08:04:22","date_gmt":"2021-05-03T12:04:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\/"},"modified":"2021-05-03T08:04:22","modified_gmt":"2021-05-03T12:04:22","slug":"iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\/","title":{"rendered":"IQVIA\u2019s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>IQVIA\u2019s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug<\/b><\/p>\n<p>RESEARCH TRIANGLE PARK, N.C.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nIQVIA (NYSE: IQV) announced today that it will collaborate with Corium, Inc \u2013 a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies \u2013 to support the launch of AZSTARYS\u2122, which was approved by the U.S. FDA on March 2, 2021. AZSTARYS is the first and only product containing a dexmethylphenidate (d-MPH) oral prodrug for the treatment of attention deficit hyperactivity disorder (ADHD) symptoms in patients aged six years and older.\n<\/p>\n<p>\n\u201cThis is an exciting milestone for Corium as we prepare to bring AZSTARYS to market and provide patients with ADHD and their clinicians a new option for rapid and extended symptom control,\u201d said Perry J. Sternberg, President and CEO of Corium. \u201cTo successfully do this, we need a partner with the expertise, resources, and technology to help us efficiently engage with clinicians and connect the right patients to this treatment. We are thrilled to be partnering with IQVIA to support and execute our commercialization strategy for AZSTARYS.\u201d\n<\/p>\n<p>\nUnder the agreement, IQVIA will deploy a tailored combination of technology, analytics, and field services to enable coordinated, effective engagements with healthcare professionals who treat ADHD. IQVIA\u2019s team of sales reps and medical liaisons will complement Corium\u2019s deep internal ADHD and commercialization expertise and customer-facing leadership. Corium will also be supported by IQVIA\u2019s Orchestrated Customer Engagement (OCE) SaaS-based platform, which connects sales, marketing, and medical with AI-enabled recommendations through an intuitive and efficient user experience.\n<\/p>\n<p>\n\u201cThis is an excellent example of how IQVIA\u2019s depth of expertise and breadth of offerings can support companies that are launching for the first time and need to maximize every engagement,\u201d said Susan Kitlas, a vice president of sales dedicated to pre-commercial clients. \u201cLeveraging IQVIA Connected Intelligence, Corium will be able to tap into the data, technology, analytics, and other resources they need to commercialize with speed, agility, and scale. We look forward to supporting Corium and bringing this valuable medicine to market for patients and families managing ADHD.\u201d\n<\/p>\n<p><b>About IQVIA<br \/>\n<br \/><\/b>IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence\u2122 delivers powerful insights with speed and agility \u2014 enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 72,000 employees, IQVIA conducts operations in more than 100 countries.\n<\/p>\n<p>\nIQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA\u2019s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.iqvia.com&amp;esheet=52421638&amp;newsitemid=20210503005234&amp;lan=en-US&amp;anchor=www.iqvia.com&amp;index=1&amp;md5=7b5f266e5dca7611e104e9010f8e132e\">www.iqvia.com<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210503005234r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210503005234\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210503005234\/en\/<\/a><\/span><\/p>\n<p>\nTor Constantino, IQVIA Media Relations (<a rel=\"nofollow\" href=\"mailto:tor.constantino@iqvia.com\">tor.constantino@iqvia.com<\/a>)<br \/>\n<br \/>+1.484.567.6732\n<\/p>\n<p>\nNick Childs, IQVIA Investor Relations (<a rel=\"nofollow\" href=\"mailto:Nchilds@us.imshealth.com\">Nchilds@us.imshealth.com<\/a>)<br \/>\n<br \/>+1.973.316.3828\n<\/p>\n<p><b>KEYWORDS:<\/b> North Carolina United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Data Management Health Technology Software Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>IQVIA\u2019s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug RESEARCH TRIANGLE PARK, N.C.&#8211;(BUSINESS WIRE)&#8211; IQVIA (NYSE: IQV) announced today that it will collaborate with Corium, Inc \u2013 a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies \u2013 to support the launch of AZSTARYS\u2122, which was approved by the U.S. FDA on March 2, 2021. AZSTARYS is the first and only product containing a dexmethylphenidate (d-MPH) oral prodrug for the treatment of attention deficit hyperactivity disorder (ADHD) symptoms in patients aged six years and older. \u201cThis is an exciting milestone for Corium as we prepare to bring AZSTARYS to market and provide patients with ADHD and their &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;IQVIA\u2019s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-485681","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IQVIA\u2019s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IQVIA\u2019s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"IQVIA\u2019s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug RESEARCH TRIANGLE PARK, N.C.&#8211;(BUSINESS WIRE)&#8211; IQVIA (NYSE: IQV) announced today that it will collaborate with Corium, Inc \u2013 a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies \u2013 to support the launch of AZSTARYS\u2122, which was approved by the U.S. FDA on March 2, 2021. AZSTARYS is the first and only product containing a dexmethylphenidate (d-MPH) oral prodrug for the treatment of attention deficit hyperactivity disorder (ADHD) symptoms in patients aged six years and older. \u201cThis is an exciting milestone for Corium as we prepare to bring AZSTARYS to market and provide patients with ADHD and their &hellip; Continue reading &quot;IQVIA\u2019s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-03T12:04:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210503005234r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IQVIA\u2019s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug\",\"datePublished\":\"2021-05-03T12:04:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\\\/\"},\"wordCount\":607,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210503005234r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\\\/\",\"name\":\"IQVIA\u2019s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210503005234r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-05-03T12:04:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210503005234r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210503005234r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IQVIA\u2019s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IQVIA\u2019s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\/","og_locale":"en_US","og_type":"article","og_title":"IQVIA\u2019s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug - Market Newsdesk","og_description":"IQVIA\u2019s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug RESEARCH TRIANGLE PARK, N.C.&#8211;(BUSINESS WIRE)&#8211; IQVIA (NYSE: IQV) announced today that it will collaborate with Corium, Inc \u2013 a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies \u2013 to support the launch of AZSTARYS\u2122, which was approved by the U.S. FDA on March 2, 2021. AZSTARYS is the first and only product containing a dexmethylphenidate (d-MPH) oral prodrug for the treatment of attention deficit hyperactivity disorder (ADHD) symptoms in patients aged six years and older. \u201cThis is an exciting milestone for Corium as we prepare to bring AZSTARYS to market and provide patients with ADHD and their &hellip; Continue reading \"IQVIA\u2019s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-03T12:04:22+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210503005234r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IQVIA\u2019s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug","datePublished":"2021-05-03T12:04:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\/"},"wordCount":607,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210503005234r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\/","name":"IQVIA\u2019s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210503005234r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-05-03T12:04:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210503005234r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210503005234r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvias-orchestrated-customer-engagement-oce-solution-chosen-to-support-the-commercial-launch-of-novel-adhd-drug\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IQVIA\u2019s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/485681","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=485681"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/485681\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=485681"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=485681"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=485681"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}